kabutan

WAKAMOTO PHARMA, First Half Ordinary Profit Loss Narrows, Jul-Sep Ordinary Profit Loss Narrows

Thu Nov 6, 2025 3:30 pm JST Earnings

4512 WAKAMOTO PHARMACEUTICAL CO.,LTD. 【J-GAAP】

Earnings Report

WAKAMOTO PHARMACEUTICAL CO.,LTD. <4512> [TSE Std] announced its financial results after the market closed on November 6th (15:30). The ordinary loss (non-consolidated) for the cumulative second quarter of the fiscal year ending March 2026 (April to September) was a reduced loss of 175 million yen (compared to a loss of 256 million yen in the same period last year).

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the ordinary profit/loss for the October to March period (second half) is expected to turn into a profit of 425 million yen (compared to a loss of 153 million yen in the same period last year).

In the most recent three-month period, from July to September (2Q), the ordinary loss improved to a deficit of 58 million yen (compared to a loss of 192 million yen in the same period last year). The operating profit/loss margin drastically improved from -9.7% in the same period last year to -2.3%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2023 3,618 -328 -319 -222 -6.4 ー Nov 6, 2023 J-GAAP
Apr - Sep, 2024 3,811 -276 -256 -141 -4.1 ー Nov 6, 2024 J-GAAP
Apr - Sep, 2025 4,382 -195 -175 -134 -3.9 ー Nov 6, 2025 J-GAAP
YoY +15.0% +29.3% +31.6% +5.0% +5.4%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 Guidance ー ー ー ー － 0 May 15, 2025 J-GAAP
Apr - Sep, 2025 Results 4,382 -195 -175 -134 -3.9 0 Nov 6, 2025 J-GAAP
Revision Rate － － － － －

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 3,978 -181 -153 205 5.9 3 May 15, 2025 J-GAAP
Oct - Mar, 2025 Guidance 5,618 395 425 334 9.6 3 Nov 6, 2025 J-GAAP
YoY +41.2% － － +62.9% +62.2%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 7,738 -195 -161 108 3.1 3 May 15, 2024 J-GAAP
Mar, 2025 7,789 -457 -409 64 1.9 3 May 15, 2025 J-GAAP
Mar, 2026 Guidance 10,000 200 250 200 5.8 3 May 15, 2025 J-GAAP
YoY +28.4% － － +212.5% +211.4%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2024 1,927 -187 -192 -130 -3.8 -9.7 Nov 6, 2024 J-GAAP
Oct - Dec, 2024 1,995 -65 -41 122 3.5 -3.3 Feb 5, 2025 J-GAAP
Jan - Mar, 2025 1,983 -116 -112 83 2.4 -5.8 May 15, 2025 J-GAAP
Apr - Jun, 2025 2,168 -143 -117 -108 -3.1 -6.6 Aug 5, 2025 J-GAAP
Jul - Sep, 2025 2,214 -52 -58 -26 -0.8 -2.3 Nov 6, 2025 J-GAAP
YoY +14.9% +72.2% +69.8% +80.0% +80.1%

Related Articles